News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Kristin Higgins, MD, City of Hope

Articles by Kristin Higgins, MD, City of Hope

Multidisciplinary Management of Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Integrating Perioperative Immunotherapy Strategies in NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Molecular testing in Patients With Metastatic NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Varied Timing of IO Therapy in Patients With Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Treating for Stage III NSCLC After Progression on Durvalumab

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Durvalumab in Stage III NSCLC Based on Performance Status

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Mediastinal Staging in Non–Small Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Kristin Higgins, MD, City of Hope,Brendon M. Stiles, MD

July 13th 2020

Latest Updated Articles

Integrating Perioperative Immunotherapy Strategies in NSCLC
July 13th 2020
ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC
July 13th 2020
Mediastinal Staging in Non–Small Cell Lung Cancer
July 13th 2020
Treating for Stage III NSCLC After Progression on Durvalumab
July 13th 2020
Varied Timing of IO Therapy in Patients With Stage III NSCLC
July 13th 2020
Multidisciplinary Management of Patients With Stage III NSCLC
July 13th 2020

Trending on OncLive

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology

MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL

GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care

SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD